1981PubMedRequires access

Schistosoma haematobium in Ajara community of Badagry. Metrifonate trials in the treatment of the disease.

Ejezie Gc, Ade-Serrano Ma

Open publisher page 2 citations

Abstract

Metrifonate, an organophosphorus cholinesterase inhibitor, which has been shown to be effective in the treatment of urinary schistosomiasis was administered orally to 145 school children aged 6-15 years at a dose of 10 mg/kg body weight in 3 doses at 14-day intervals. Urinalysis was carried out to determine egg out-put, haematuria and proteinuria. None of the subjects was anaemic before treatment, 78.6% tolerated the drug well while 21.4% had minimal and transient side-effects. 47.6% with light infections, 29.9% with moderate infections and 5.1% with heavy infections, had no ova of S. haematobium in their urine after the first dose. The pre- and post-treatment urinalysis showed very significant reductions in the number of subjects with haematuria and proteinuria. However, some of those with no ova of S. haematobium in their urine still had haematuria and proteinuria. The determination of these parameters indicates the intensity of infection and can be used in assessing the results of chemotherapy.

About this research paper

What this paper is about

Metrifonate, an organophosphorus cholinesterase inhibitor, which has been shown to be effective in the treatment of urinary schistosomiasis was administered orally to 145 school children aged 6-15 years at a dose of 10 mg/kg body weight in 3 doses at 14-day intervals. Urinalysis was carried out to determine egg out-put, haematuria and proteinuria. None of the subjects was anaemic before treatment, 78.6% tolerated the drug well while 21.4% had minimal and transient side-effects. 47.6% with light infections, 29.9% with moderate infections and 5.1% with heavy infections, had no ova of S. haematobium in their urine after the first dose. The pre- and post-treatment urinalysis showed very significant reductions in the number of subjects with haematuria and proteinuria. However, some of those with no ova of S. haematobium in their urine still had haematuria and proteinuria. The determination of these parameters indicates the intensity of infection and can be used in assessing the results of chemotherapy.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Metrifonate, an organophosphorus cholinesterase inhibitor, which has been shown to be effective in the treatment of urinary schistosomiasis was administered orally to 145 school children aged 6-15 years at a dose of 10 mg/kg body weight in 3 doses at 14-day intervals. Urinalysis was carried out to determine egg out-put, haematuria and proteinuria. None of the subjects was anaemic before treatment, 78.6% tolerated the drug well while 21.4% had minimal and transient side-effects. 47.6% with light infections, 29.9% with moderate infections and 5.1% with heavy infections, had no ova of S. haematobium in their urine after the first dose. The pre- and post-treatment urinalysis showed very significant reductions in the number of subjects with haematuria and proteinuria. However, some of those with no ova of S. haematobium in their urine still had haematuria and proteinuria. The determination of these parameters indicates the intensity of infection and can be used in assessing the results of chemotherapy.

Key concepts: Schistosoma haematobium, Urinalysis, Proteinuria, Urine, Schistosomiasis, Helminthiasis, Medicine, Gastroenterology

Related papers

Back to paper searchBrowse research topicsOriginal source
Schistosoma haematobium in Ajara community of Badagry. Metrifonate trials in the treatment of the disease. — Research Paper | ScholarLens